Literature DB >> 33712911

Supportive oncodermatology-a narrative review of its utility and the way forward.

Valencia Long1, Ellie Ci-En Choi2, Chris Lixian Tan2.   

Abstract

Supportive oncodermatology is an interdisciplinary field, emerging due to increasing dermatological morbidity in patients with cancer and the recognition of the need for greater collaborative and integrated care to improve patient outcomes. These two unique fields (Oncology and Dermatology) may be integrated in various ways, such as through specialised combined clinics, protocols for expedited access, multidisciplinary groups and meetings, and the development of best practices guidelines. This narrative review consolidates the small but growing literature surrounding supportive oncodermatology; discusses the potential benefit and disadvantages, and areas for future research; and suggests a framework for implementation.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Cutaneous toxicities; MASCC; Supportive care; Supportive oncodermatology

Year:  2021        PMID: 33712911     DOI: 10.1007/s00520-021-06124-w

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  15 in total

1.  Repair of oligodeoxynucleotides containing O6-methylguanine by O6-alkylguanine-DNA-alkyltransferase.

Authors:  D Scicchitano; R A Jones; S Kuzmich; B Gaffney; D D Lasko; J M Essigmann; A E Pegg
Journal:  Carcinogenesis       Date:  1986-08       Impact factor: 4.944

2.  Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  J B A G Haanen; F Carbonnel; C Robert; K M Kerr; S Peters; J Larkin; K Jordan
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

3.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal:  J Clin Oncol       Date:  2018-02-14       Impact factor: 44.544

4.  Evaluation of a Comprehensive Skin Toxicity Program for Patients Treated With Epidermal Growth Factor Receptor Inhibitors at a Cancer Treatment Center.

Authors:  Zizi Yu; Edward Christopher Dee; Daniel Q Bach; Arash Mostaghimi; Nicole R LeBoeuf
Journal:  JAMA Dermatol       Date:  2020-10-01       Impact factor: 10.282

5.  Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors.

Authors:  Pietro Sollena; Vasiliki Nikolaou; Nikolaos Soupos; Elias Kotteas; Dimitra Voudouri; Alexandros J Stratigos; Davide Fattore; Maria Carmela Annunziata; Armando Orlandi; Lucia Di Nardo; Zoe Apalla; Florian Deilhes; Maria Concetta Romano; Gabriella Fabbrocini; Vincent Sibaud; Ketty Peris
Journal:  Breast Cancer Res Treat       Date:  2020-09-10       Impact factor: 4.872

Review 6.  Acetaldehyde hydrate and carbonic anhydrase: possible roles in the inhibition of brain aldehyde dehydrogenase.

Authors:  R P Sheridan; C A Deakyne; L C Allen
Journal:  Adv Exp Med Biol       Date:  1980       Impact factor: 2.622

7.  Daily baseline skin care in the prevention, treatment, and supportive care of skin toxicity in oncology patients: recommendations from a multinational expert panel.

Authors:  René-Jean Bensadoun; Phillipe Humbert; Jean Krutman; Thomas Luger; Raoul Triller; André Rougier; Sophie Seite; Brigitte Dreno
Journal:  Cancer Manag Res       Date:  2013-12-09       Impact factor: 3.989

8.  Evaluation of supportive and barrier-protective skin care products in the daily prevention and treatment of cutaneous toxicity during systemic chemotherapy.

Authors:  Diana Lüftner; Veronica Dell'Acqua; Frédéric Selle; Ahmed Khalil; Maria Cristina Leonardi; Alejandro De La Torre Tomás; George Shenouda; Jesus Romero Fernandez; Roberto Orecchia; Dominique Moyal; Sophie Seité
Journal:  Onco Targets Ther       Date:  2018-09-17       Impact factor: 4.147

Review 9.  Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Hong-bing Liu; Ying Wu; Tang-feng Lv; Yan-wen Yao; Yong-ying Xiao; Dong-mei Yuan; Yong Song
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

Review 10.  Algorithm for dermocosmetic use in the management of cutaneous side-effects associated with targeted therapy in oncology.

Authors:  B Dreno; R J Bensadoun; P Humbert; J Krutmann; T Luger; R Triller; A Rougier; S Seité
Journal:  J Eur Acad Dermatol Venereol       Date:  2013-02-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.